Zhang et al. modified our previously developed catadine-loaded BR2 liposomes with anti-CA IX antibodies, which improved their targeted delivery of drugs to cancer cells through the highly expressed carbonic anhydrase IX (CA IX) receptor. This evidence concerns the gene CA9 and cancer.